Commercial Immunoassays in Biomarkers Studies: Researchers Beware!

被引：24

作者：

Rifai, Nader ^{[1
,2
]}

Watson, Ian D. ^{[3
]}

Miller, W. Greg ^{[4
]}

机构：

[1] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA

[2] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA

[3] Aintree Univ Hosp NHS Fdn Trust, Dept Clin Chem, Liverpool L9 7AL, Merseyside, England

[4] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA

来源：

CLINICAL CHEMISTRY | 2012年 / 58卷 / 10期

关键词：

DISCOVERY;

D O I：

10.1373/clinchem.2012.192351

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

100118 [医学信息学]; 100208 [临床检验诊断学];

摘要：

引用

页码：1387 / 1388

页数：2

共 6 条

[1]

[Anonymous], 2012, ELSEVIER SCI INT C S

[2]

[Anonymous], Research Portfolio Online Reporting Tools (RePORT). Date unknown

[3]

A recipe for disaster [J].

Git, Anna .

NATURE, 2012, 484 (7395) :439-440

[4]

Protein biomarker discovery and validation: the long and uncertain path to clinical utility [J].

Rifai, Nader ;

Gillette, Michael A. ;

Carr, Steven A. .

NATURE BIOTECHNOLOGY, 2006, 24 (08) :971-983

[5]

Advances in validation, risk and uncertainty assessment of bioanalytical methods [J].

Rozet, E. ;

Marini, R. D. ;

Ziemons, E. ;

Boulanger, B. ;

Hubert, Ph .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 55 (04) :848-858

[6]

Mass Spectrometry in Biomarker Applications: From Untargeted Discovery to Targeted Verification, and Implications for Platform Convergence and Clinical Application [J].

Smith, Richard D. .

CLINICAL CHEMISTRY, 2012, 58 (03) :528-530

← 1 →